Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Maria L. Maccecchini
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 7
- Beta
- 1.24
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -17.99
Financials
Net Income
$-14.82MEBITDA
$-14.38MFree Cash Flow
$-21.91MEPS (diluted)
$-0.39Shares Outstanding (diluted)
37.52M+450.3%Operating Expenses
$14.38BCash & Debt
$18.73MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-28.85M | $-1.40 |
| 2024 | $0.00 | $-24.59M | $-2.02 |
| 2023 | $0.00 | $-56.20M | $-6.23 |
| 2022 | $0.00 | $-25.33M | $-3.10 |
| 2021 | $0.00 | $-14.49M | $-1.90 |
| 2020 | $0.00 | $-5.46M | $-0.87 |
| 2019 | $0.00 | $-991.0K | $-0.14 |
| 2018 | $0.00 | $-714.0K | $-0.10 |
| 2017 | $0.00 | $-682.0K | $-0.10 |
Valuation
ANVShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60-40.00%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·13d ago·Negative
…ve Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer's Disease MALVERN, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced a collaboration with Weave Bio, an AI platform for regulatory content and knowledge …
View source ↗ - Newszacks.com·27d ago·Neutral
Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Annovis Bio (ANVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
View source ↗ - Newsmarketbeat.com·33d ago·Negative
Annovis Bio Targets March 2027 Alzheimer's Readout, Prepares Rolling NDA Annovis Bio NYSE: ANVS said it expects to report top-line results from the six-month portion of its pivotal Phase III Alzheimer's disease trial in March 2027, while preparing a rolling new drug application, or NDA, that management said could begin in May if the study meets its efficacy requirements.
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results MALVERN, Pa., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided business updates and reported financial results for the second quarter ended June 30, 2026.
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.30 per share
Typical surprise -2.8% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-0.40 vs $-0.45beat
- Fri, May 15$-0.63 vs $-0.40miss
- Mon, Mar 16$-0.39 vs $-0.31miss
- Wed, Nov 12$-0.37 vs $-0.36miss
- Tue, Aug 12$-0.32 vs $-0.36beat
- Tue, May 13$-0.32 vs $-0.47beat
Estimates and results for ANVS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ANVS officers and directors.
- Bought
- $4.5m
- Sold
- —
19 trades
0 trades
- Hoffman Michael Bbought
- Hoffman Michael Bbought
- Hoffman Michael Bbought
- Hoffman Michael Bbought
- Hoffman Michael Bbought
- Hoffman Michael Bbought
- Hoffman Michael Bbought
- Hoffman Michael Bbought
81 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ANVS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.